{"pmid":32396985,"title":"Risk of COVID-19 in young kidney transplant recipients. Results from a single-center observational study.","text":["Risk of COVID-19 in young kidney transplant recipients. Results from a single-center observational study.","Coronavirus Disease 2019 (COVID-19) represents a global public health emergency, recently taken on pandemic proportions, with over 2.7 million confirmed cases worldwide(1). Children/young adults seem to have a less severe clinical manifestation of COVID-19 (2), but data on disease susceptibility in pediatric transplant recipients on chronic immunosuppressive therapy are limited (3, 4). This poses major uncertainties regarding pediatric transplant activity and management of anti-rejection therapy.","Clin Transplant","Angeletti, Andrea","Trivelli, Antonella","Magnasco, Alberto","Drovandi, Stefania","Sanguineri, Francesca","Santaniello, Maria","Ferrando, Giulia","Forno, Roberto","Cipresso, Gaia","Tripodi, Gino","Riella, Leonardo V","Cravedi, Paolo","Ghiggeri, Gian Marco","32396985"],"abstract":["Coronavirus Disease 2019 (COVID-19) represents a global public health emergency, recently taken on pandemic proportions, with over 2.7 million confirmed cases worldwide(1). Children/young adults seem to have a less severe clinical manifestation of COVID-19 (2), but data on disease susceptibility in pediatric transplant recipients on chronic immunosuppressive therapy are limited (3, 4). This poses major uncertainties regarding pediatric transplant activity and management of anti-rejection therapy."],"journal":"Clin Transplant","authors":["Angeletti, Andrea","Trivelli, Antonella","Magnasco, Alberto","Drovandi, Stefania","Sanguineri, Francesca","Santaniello, Maria","Ferrando, Giulia","Forno, Roberto","Cipresso, Gaia","Tripodi, Gino","Riella, Leonardo V","Cravedi, Paolo","Ghiggeri, Gian Marco"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32396985","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/ctr.13889","topics":["Treatment","Prevention"],"weight":1,"_version_":1666627827896680449,"score":9.490897,"similar":[{"pmid":32282986,"title":"Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients.","text":["Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients.","Over 1 000 000 cases of coronavirus disease 2019 (COVID-19) have been confirmed since the worldwide outbreak began. Not enough data on infected solid organ transplant (SOT) recipients are available, especially data about the management of immunosuppressants. We report two cases of COVID-19 in two transplant recipients, with different treatments and prognoses. The first patient received liver transplantation due to hepatitis B virus-related hepatocellular carcinoma and was confirmed to have COVID-19 9 days later. Following a treatment regimen consisting of discontinued immunosuppressant use and low-dose methylprednisolone-based therapy, the patient developed acute rejection but eventually recovered. The other patient had undergone a renal transplant from a living-related donor 17 years ago, and was admitted to the hospital because of persistent fever. This patient was also diagnosed with COVID-19. His treatment regimen consisted of reduced immunosuppressant use. No signs of rejection were observed during the regimen. In the end, the patient successfully recovered from COVID-19. These effectively treated cases can provide a basis for immunosuppressant management of COVID-19-positive SOT recipients.","Am J Transplant","Zhong, Zibiao","Zhang, Qiuyan","Xia, Haoyang","Wang, Aiping","Liang, Wenjin","Zhou, Wei","Zhou, Lihua","Liu, Xiao","Rao, Lingzhang","Li, Zhifeng","Peng, Zhiyong","Mo, Pingzheng","Xiong, Yong","Ye, Shaojun","Wang, Yanfeng","Ye, Qifa","32282986"],"abstract":["Over 1 000 000 cases of coronavirus disease 2019 (COVID-19) have been confirmed since the worldwide outbreak began. Not enough data on infected solid organ transplant (SOT) recipients are available, especially data about the management of immunosuppressants. We report two cases of COVID-19 in two transplant recipients, with different treatments and prognoses. The first patient received liver transplantation due to hepatitis B virus-related hepatocellular carcinoma and was confirmed to have COVID-19 9 days later. Following a treatment regimen consisting of discontinued immunosuppressant use and low-dose methylprednisolone-based therapy, the patient developed acute rejection but eventually recovered. The other patient had undergone a renal transplant from a living-related donor 17 years ago, and was admitted to the hospital because of persistent fever. This patient was also diagnosed with COVID-19. His treatment regimen consisted of reduced immunosuppressant use. No signs of rejection were observed during the regimen. In the end, the patient successfully recovered from COVID-19. These effectively treated cases can provide a basis for immunosuppressant management of COVID-19-positive SOT recipients."],"journal":"Am J Transplant","authors":["Zhong, Zibiao","Zhang, Qiuyan","Xia, Haoyang","Wang, Aiping","Liang, Wenjin","Zhou, Wei","Zhou, Lihua","Liu, Xiao","Rao, Lingzhang","Li, Zhifeng","Peng, Zhiyong","Mo, Pingzheng","Xiong, Yong","Ye, Shaojun","Wang, Yanfeng","Ye, Qifa"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32282986","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/ajt.15928","keywords":["covid-19","clinical characteristics","immunosuppressant","solid organ transplant recipient"],"e_drugs":["Methylprednisolone"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138491464974336,"score":191.63037},{"pmid":32415905,"title":"Coronavirus disease 2019 in renal transplant recipients: report of two cases.","text":["Coronavirus disease 2019 in renal transplant recipients: report of two cases.","Coronavirus disease 2019 (COVID-19) has been a pandemic worldwide. The data about COVID-19 in renal transplant recipient is deficiency. Herein we report two COVID-19 cases in renal transplant recipients. Both cases were discharged following a treatment regimen including discontinued immunosuppressant and low-dose methylprednisolone-based therapy. There were no signs of rejection during the treatment. These successfully treated cases can provide helpful information about the management of COVID-19 in renal transplant recipients.","Transpl Infect Dis","Cheng, D R","Wen, J Q","Liu, Z Z","Lv, T F","Chen, J S","32415905"],"abstract":["Coronavirus disease 2019 (COVID-19) has been a pandemic worldwide. The data about COVID-19 in renal transplant recipient is deficiency. Herein we report two COVID-19 cases in renal transplant recipients. Both cases were discharged following a treatment regimen including discontinued immunosuppressant and low-dose methylprednisolone-based therapy. There were no signs of rejection during the treatment. These successfully treated cases can provide helpful information about the management of COVID-19 in renal transplant recipients."],"journal":"Transpl Infect Dis","authors":["Cheng, D R","Wen, J Q","Liu, Z Z","Lv, T F","Chen, J S"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32415905","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/tid.13329","keywords":["covid-19","sars-cov-2","immunosuppressant","methylprednisolone","renal transplant recipient"],"e_drugs":["Methylprednisolone"],"topics":["Case Report"],"weight":1,"_version_":1666991242670505984,"score":184.7287},{"pmid":32460390,"title":"Covid-19 in solid organ transplant recipients: A single center experience.","text":["Covid-19 in solid organ transplant recipients: A single center experience.","BACKGROUND: Solid organ transplant (SOT) recipients may be at risk for severe COVID-19. Data on the clinical course of COVID-19 in immunosuppressed patients are limited and the effective treatment strategy for these patients is unknown. METHODS: We describe our institutional experience with COVID-19 in SOT. Demographic, clinical and treatment data were extracted from the electronic patient files. RESULTS: A total of 23 SOT transplant recipients suffering from COVID-19 were identified (n = 3 heart; n =15 kidney; n = 1 kidney-after-heart; n = 3 lung and n = 1 liver transplant recipient). The presenting symptoms were similar to non-immunocompromised patients Eighty-three percent (19/23) of the patients required hospitalization but only two of these were transferred to the intensive care unit. Five patients died from COVID-19; all had high Clinical Frailty scores. In four of these patients, mechanical ventilation was deemed futile. In 57% of patients, the immunosuppressive therapy was not changed and only 3 patients were treated with chloroquine. Most patients recovered without experimental anti-viral therapy. CONCLUSIONS: Modification of the immunosuppressive regimen alone could be a therapeutic option for SOT recipients suffering from moderate to severe COVID-19. Pre-existent frailty is associated with death from COVID-19.","Transpl Int","Hoek, Rogier A S","Manintveld, Olivier C","Betjes, Michiel G H","Hellemons, Merel E","Seghers, Leonard","van Kampen, Jeroen A A","Caliskan, Kadir","van de Wetering, Jacqueline","van den Hoogen, Martijn","Metselaar, Herold J","Hesselink, Dennis A","32460390"],"abstract":["BACKGROUND: Solid organ transplant (SOT) recipients may be at risk for severe COVID-19. Data on the clinical course of COVID-19 in immunosuppressed patients are limited and the effective treatment strategy for these patients is unknown. METHODS: We describe our institutional experience with COVID-19 in SOT. Demographic, clinical and treatment data were extracted from the electronic patient files. RESULTS: A total of 23 SOT transplant recipients suffering from COVID-19 were identified (n = 3 heart; n =15 kidney; n = 1 kidney-after-heart; n = 3 lung and n = 1 liver transplant recipient). The presenting symptoms were similar to non-immunocompromised patients Eighty-three percent (19/23) of the patients required hospitalization but only two of these were transferred to the intensive care unit. Five patients died from COVID-19; all had high Clinical Frailty scores. In four of these patients, mechanical ventilation was deemed futile. In 57% of patients, the immunosuppressive therapy was not changed and only 3 patients were treated with chloroquine. Most patients recovered without experimental anti-viral therapy. CONCLUSIONS: Modification of the immunosuppressive regimen alone could be a therapeutic option for SOT recipients suffering from moderate to severe COVID-19. Pre-existent frailty is associated with death from COVID-19."],"journal":"Transpl Int","authors":["Hoek, Rogier A S","Manintveld, Olivier C","Betjes, Michiel G H","Hellemons, Merel E","Seghers, Leonard","van Kampen, Jeroen A A","Caliskan, Kadir","van de Wetering, Jacqueline","van den Hoogen, Martijn","Metselaar, Herold J","Hesselink, Dennis A"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32460390","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/tri.13662","keywords":["covid-19","sars-cov-2","organ transplantation","solid organ transplantation"],"topics":["Treatment"],"weight":1,"_version_":1667967698947014659,"score":180.85085},{"pmid":32304488,"pmcid":"PMC7188032","title":"Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.","text":["Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.","BACKGROUND: COVID-19 is a novel infectious disease caused by the severe acute respiratory distress (SARS)-corona virus-2 (SARS-CoV-2). Several therapeutic options are currently emerging but none with universal consensus or proven efficacy. Solid organ transplant recipients are perceived to be at increased risk of severe COVID-19 because of their immunosuppressed conditions due to chronic use of immunosuppressive drugs. It is therefore likely that solid organ transplant recipients will be treated with these experimental antivirals. METHODS: This article is not intended to provide a systematic literature review on investigational treatments tested against COVID-19; rather, the authors aim to provide recommendations for therapeutic drug monitoring of immunosuppressive drugs in transplant recipients infected with SARS-CoV-2 based on a review of existing data in the literature. RESULTS: Management of drug-drug interactions between investigational anti-SARS-CoV-2 drugs and immunosuppressants is a complex task for the clinician. Adequate immunosuppression is necessary to prevent graft rejection while, if critically ill, the patient may benefit from pharmacotherapeutic interventions directed at limiting SARS-CoV-2 viral replication. Maintaining immunosuppressive drug concentrations within the desired therapeutic range requires a highly individualized approach that is complicated by the pandemic context and lack of hindsight. CONCLUSIONS: With the present manuscript, the authors inform the clinician about the potential interactions of experimental COVID-19 treatments with immunosuppressive drugs used in transplantation. Recommendations regarding therapeutic drug monitoring and dose adjustments in the context of COVID-19 are provided.","Ther Drug Monit","Elens, Laure","Langman, Loralie J","Hesselink, Dennis A","Bergan, Stein","Moes, Dirk Jan A R","Molinaro, Mariadelfina","Venkataramanan, Raman","Lemaitre, Florian","32304488"],"abstract":["BACKGROUND: COVID-19 is a novel infectious disease caused by the severe acute respiratory distress (SARS)-corona virus-2 (SARS-CoV-2). Several therapeutic options are currently emerging but none with universal consensus or proven efficacy. Solid organ transplant recipients are perceived to be at increased risk of severe COVID-19 because of their immunosuppressed conditions due to chronic use of immunosuppressive drugs. It is therefore likely that solid organ transplant recipients will be treated with these experimental antivirals. METHODS: This article is not intended to provide a systematic literature review on investigational treatments tested against COVID-19; rather, the authors aim to provide recommendations for therapeutic drug monitoring of immunosuppressive drugs in transplant recipients infected with SARS-CoV-2 based on a review of existing data in the literature. RESULTS: Management of drug-drug interactions between investigational anti-SARS-CoV-2 drugs and immunosuppressants is a complex task for the clinician. Adequate immunosuppression is necessary to prevent graft rejection while, if critically ill, the patient may benefit from pharmacotherapeutic interventions directed at limiting SARS-CoV-2 viral replication. Maintaining immunosuppressive drug concentrations within the desired therapeutic range requires a highly individualized approach that is complicated by the pandemic context and lack of hindsight. CONCLUSIONS: With the present manuscript, the authors inform the clinician about the potential interactions of experimental COVID-19 treatments with immunosuppressive drugs used in transplantation. Recommendations regarding therapeutic drug monitoring and dose adjustments in the context of COVID-19 are provided."],"journal":"Ther Drug Monit","authors":["Elens, Laure","Langman, Loralie J","Hesselink, Dennis A","Bergan, Stein","Moes, Dirk Jan A R","Molinaro, Mariadelfina","Venkataramanan, Raman","Lemaitre, Florian"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304488","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1097/FTD.0000000000000761","topics":["Treatment"],"weight":1,"_version_":1666138491079098368,"score":180.03458},{"pmid":32439237,"title":"Liver transplantation in the era of COVID-19.","text":["Liver transplantation in the era of COVID-19.","Liver transplantation is considered the ultimate solution for patients with end-stage chronic liver disease or acute liver failure. Patients with liver transplant need special care starting from preoperative preparation, surgical intervention ending with postoperative care. Transplanted patients have to receive immunosuppressive therapy to prevent rejection. Such a state of immune suppression could predispose to different types of infections in liver transplant recipients. Currently, the world is suffering a pandemic caused by a new strain of the coronavirus family called COVID-19. Certain infection control precautions are needed to protect immunocompromised and vulnerable patients, including liver transplant candidates and recipients from acquiring COVID-19 infection. Restricting non-transplant elective surgical procedures, managing transplant patients in separate outpatient clinics, and in-patient wards can prevent transmission of infection both to patients and healthcare workers. Telemedicine can help in the triage of patients to screen for symptoms of COVID-19 before their regular appointment. Management of immunosuppressive therapy and drug-drug interactions in liver transplant recipients infected with COVID-19 should be cautiously practiced to prevent rejection and effectively treat the underlying infection. In this report, we are trying to summarize available evidence about different aspects of the management of liver transplant candidates and recipients in the era of COVID-19.","Arab J Gastroenterol","El Kassas, Mohamed","Alboraie, Mohamed","Al Balakosy, Amira","Abdeen, Nermeen","Afify, Shimaa","Abdalgaber, Mohammad","Sherief, Ahmed F","Madkour, Ahmad","Abdellah Ahmed, Mohamed","Eltabbakh, Mohamed","Salaheldin, Mohamed","Wifi, Mohamed-Naguib","32439237"],"abstract":["Liver transplantation is considered the ultimate solution for patients with end-stage chronic liver disease or acute liver failure. Patients with liver transplant need special care starting from preoperative preparation, surgical intervention ending with postoperative care. Transplanted patients have to receive immunosuppressive therapy to prevent rejection. Such a state of immune suppression could predispose to different types of infections in liver transplant recipients. Currently, the world is suffering a pandemic caused by a new strain of the coronavirus family called COVID-19. Certain infection control precautions are needed to protect immunocompromised and vulnerable patients, including liver transplant candidates and recipients from acquiring COVID-19 infection. Restricting non-transplant elective surgical procedures, managing transplant patients in separate outpatient clinics, and in-patient wards can prevent transmission of infection both to patients and healthcare workers. Telemedicine can help in the triage of patients to screen for symptoms of COVID-19 before their regular appointment. Management of immunosuppressive therapy and drug-drug interactions in liver transplant recipients infected with COVID-19 should be cautiously practiced to prevent rejection and effectively treat the underlying infection. In this report, we are trying to summarize available evidence about different aspects of the management of liver transplant candidates and recipients in the era of COVID-19."],"journal":"Arab J Gastroenterol","authors":["El Kassas, Mohamed","Alboraie, Mohamed","Al Balakosy, Amira","Abdeen, Nermeen","Afify, Shimaa","Abdalgaber, Mohammad","Sherief, Ahmed F","Madkour, Ahmad","Abdellah Ahmed, Mohamed","Eltabbakh, Mohamed","Salaheldin, Mohamed","Wifi, Mohamed-Naguib"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32439237","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.ajg.2020.04.019","keywords":["covid-19","coronavirus","liver transplantation"],"topics":["Prevention"],"weight":1,"_version_":1667523504770121729,"score":164.46646}]}